Physician profile
Wayne B Lucas
NPI 1932141223
$5,788.23
in general payments reported to CMS, 2019-2025
35 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $265 · 2021: $221 · 2022: $663 · 2023: $843 · 2024: $1,755 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Education: $38.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,827.72 |
| Education | $38.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,263.53 | 2019-2025 | |
| Janssen Biotech, INC. | $394.39 | 2019-2025 | Tremfya, Stelara, Simponi |
| Steris Corporation | $358.37 | 2022-2024 | |
| Gilead Sciences, INC. | $337.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $292.90 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $196.14 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $178.27 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $175.36 | 2024-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $147.39 | 2024 | Tremfya |
| Celgene Corporation | $128.63 | 2023-2024 | Zeposia |
| Novo Nordisk INC | $122.42 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $120.33 | 2022-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $117.55 | 2022-2024 | Linzess |
| Olympus America INC. | $112.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.64 | 2019-2023 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $67.16 | 2019 | |
| Fresenius Kabi USA, LLC | $66.12 | 2023-2024 | Idacio |
| Pentax of America, INC. | $65.88 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $57.92 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $56.21 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $50.76 | 2021-2023 | |
| Lilly USA, LLC | $43.76 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $43.16 | 2024 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $43.00 | 2025 | Rezdiffra |
| Amgen INC. | $38.69 | 2021-2023 | Avsola, Amjevita |
| Enterra Medical, INC. | $36.85 | 2025 | |
| Romark Laboratories, Lc | $32.43 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.64 | 2024 | Givlaari |
| Pharmacosmos Therapeutics INC. | $22.83 | 2025 | Monoferric |
| Sandoz INC. | $21.40 | 2024 | Hyrimoz |
| Ardelyx, INC. | $20.17 | 2023 | Ibsrela |
| Ucb, INC. | $18.27 | 2019 | |
| Laborie Medical Technologies Corp. | $13.63 | 2024 | |
| Dynavax Technologies Corporation | $12.63 | 2020 | |
| Allergan, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.